Business · 26/02/2020
FDA Updates Guidance for In Vitro Diagnostic Devices Under CLIA Waiver Program
The Food and Drug Administration (FDA) has released a final guidance document updating recommendations for manufacturers of in vitro diagnostic devices seeking CLIA waiver applications, incorporating changes from the 21st Century Cures Act
Original source language: Federal Register — Food and Drug AdministrationOpen original release →